SCHEMBL4864401

SCHEMBL4864401

Fc1cccc(CCNc2nc(C3CCCCC3)nc3ccccc23)c1

nearest known ligand 0.65

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 3/20 0.65
LMNA P02545 1/20 0.57
MAPT P10636 1/20 0.57
GBA1 P04062 1/20 0.56
OGG1 O15527 1/20 0.50
APP P05067 9/20 0.49
BCHE P06276 6/20 0.49
ACHE P22303 6/20 0.49
CCNE2 O96020 1/20 0.47
CCNE1 P24864 1/20 0.47
CDK2 P24941 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.44
CSNK2A2 P19784 1/20 0.43
CSNK2A1 P68400 1/20 0.43
TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4866829 0.89 PDE5A (0.78) PDE5ALMNAMAPTOGG1APP
SCHEMBL4856782 0.89 PDE5A (0.77) PDE5ALMNAGBA1OGG1APP
SCHEMBL4864327 0.81 PDE5A (0.72) PDE5ALMNAGBA1OGG1APP
SCHEMBL4095293 0.79 PDE5A (1.00) PDE5ALMNAMAPTGBA1OGG1
SCHEMBL4864860 0.78 LMNA (0.65) PDE5ALMNAMAPTGBA1APP
SCHEMBL4867110 0.78 PDE5A (0.70) PDE5ALMNAMAPTGBA1OGG1
SCHEMBL4857481 0.78 LMNA (0.64) PDE5ALMNAMAPTGBA1APP
SCHEMBL4856772 0.78 GBA1 (0.82) PDE5ALMNAMAPTGBA1APP
SCHEMBL4867046 0.76 PDE5A (0.73) PDE5AOGG1APPBCHEACHE
SCHEMBL5104398 0.76 CCNE2 (0.63) PDE5ALMNAMAPTGBA1APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US claimed
JP-2008526734-A 2008-07-24 JP claimed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP claimed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO claimed
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US disclosed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP disclosed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY GPR119, GCKR, GLP1R PDE5A 204/4885LMNA 3549/4885MAPT 4050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.